Abeona Therapeutics Inc. fell 39.1% on Monday, November 9, 2026, on 13,570,800 shares, 8.3 times its average daily volume. Headlines around the move:
Abeona Therapeutics Inc. (ABEO:NASDAQ) closed at $2.42 on November 13, 2026, up 5.68% on the day. The stock trades 68.4% below its 52-week high of $7.65 and 15.8% above its 52-week low of $2.09. Over the past year, it lost 45.6%. Abeona Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, ABEO closed higher on 109 days (43%). Its best day was May 4, 2026 (+9.58%) and its worst was November 9, 2026 (-39.09%). The stock moved 10% or more in a single session 2 times.
Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases....
Find more stocks like ABEO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.